Slack N.H., Bross I.D.J.
The influence of site metastasis on tumor growth and
response to chemotherapy // Br. J. Cancer. — 1975. — V. 32. — P. 78 86.
Sledge G.W., Neuberg D., Ingle J.,
è ñîàâò. Phase III trial of doxorubicin (A) versus
paclitaxel (T) versus doxorubicin + paclitaxel (A+T) as first line therapy for metastatic
breast cancer (MBC): an intergroup trial // Proc Annu. Meet. Am. Soc .Clin. Oncol. —
1998. — V. 17. — 1a. Abstract 2.
Smalley R.V.
A comparison of cyclophosphamide, adriamycin, 5 fluorouracili, vin
cristine, prednisone (CAFVP) in patients with metastatic breast cancer // Cancer. — 1977.
— V. 40. — P. 625 632.
Smalley R., Mayer+Scogna D., Malmud L.
Prolonged response to chemotherapy
(CAF) in patients with metastases to bone only stage IV breast cancer // Proc. Am. Assoc.
Cancer Res. — 1979. — V. 20. — 347.
Smalley R.V., Scogna D.M., Malmud L.S.
Edvanced breast cancer with bone — only
metastases. A chemotherapeutically responsive pattern of metastases // Am. J. Clin.
Oncol. — 1982. — V. 5(2). — P.161 166.
Smith I.E., Fitzharris B.M., Mc Kinna J.A.
Aminoglutethimide in treatment of
metastatic breast carcinoma // Lancet II. — 1978. — P. 646 649.
Smith I.E., Harris A.L., Morgan M.
Tamoxifen versus aminoglutethimidi in
advanced breast carcinoma: a randomized cross over trial // Brit. Med. J. — 1981. —
V.28(283). — P. 1432 1434.
Smith I.E., Harris A.L., Stuart+Harris R., Ford H.T., Gazet J.C., White H., Harmer
C.L., Carr I., Mc Kinna J.A., Morgan M.
Combination treatment with tamoxifen and
aminoglutethimide in advanced breast cancer // Brit. Med. J. (Clin. Res.). 1983. —
V. 21(286). — P.1615 1616.
Smith J.R., Macaulay V.
Comparison of different encocrine therapies in manage
ment of bone metastases from breast carcinoma // J. Royal. Soc. Med. — 1985. —
V. 78.(Suppl. 9). — P.15 17.
Smith G., Henderson I.C.
New treatments for breast cancer // Sem. Oncol. — 1996. —
V. 23(4). — P. 506 528.
Soderlund V.
Radiological diagnosis of skeletal metastases // Eur. Radiol. — 1996. —
V. 6(5). — P. 587 595.
Soletormos G., Nielsen D., Schioler V., Skovsgaard T., Winkel P., Mouridsen H.T.,
Dombernowsky P.
A novel method for monitoring high risk breast cancer with tumor mark
ers: CA 15.3 compared to CEA and TPA // Ann. Oncol. — 1993. — V. 4(10). — P. 861
869.
Solomayer E.F., Diel I.J., Wallwiener D., Bode S., Meyberg G., Sillem M., Gollan C.,
Kramer M.D., Krainick U., Bastert G.
Prognostic relevance of urokinase plasminogen acti
vator detection in micrometastatic cells in the bone marrow of patients with primary breast
cancer // Br. J. Cancer. — 1997. — V. 76(6). — P. 812 818.
Sonoo H., Shimozuma K., Kurebayashi J., Ohta K., Kiyono T.
Systemic therapy, pain
relief and quality of life of breast cancer patients with bone metastasis // Gan To Kagaku
Ryoho. — 1995. — V. 22 (Suppl. 1). — P. 10 15.
Spielman M., Kalla S., Llombart+Cussac A.,
è ñîàâò. Activity of gemcitabine in
metastatic breast cancer (MBC) patients previously treated with anthracycline containing
regimens // Eur. J. Cancer. — 1997. — V. 33(suppl 8). — A663 (Abstract).
Stally R.
The managment of disseminated breast cancer // In: Principles of Cancer
Treatment. Eds. S. Carter è ñîàâò. — 1981. — V. 4. — P. 327 341.
248
Êîñòíûå ìåòàñòàçû ðàêà ìîëî÷íîé æåëåçû
